The immunomodulator Sepsivac would be given to the coronavirus patients as vaccine so that the patients don't redevelop infection, said Dr.
Ram Vishwakarma of PGIMER Chandigarh NEW DELHI : The PGIMER Chandigarh on Wednesday said it has started the clinical trial of Sepsivac on asymptomatic coronavirus patients amid rising number of COVID-19 patients in India.
Dr. Ram Vishwakarma, coordinator of trial program at Post Graduate Institute of Medical Education and Research in Chandigarh, said the immunomodulator Sepsivac would be given to the coronavirus patients as vaccine so that the patients don't redevelop infection, news agency ANI reported.